関連する実験動画
Updated: Jan 8, 2026
01:27
Pulmonary Embolism III: Nursing Management
Published on: June 19, 2025
320
まとめ
免疫グロブリン遺伝子発現の特異性は,強化剤によってのみ制御されるわけではありません. プロモーターおよび内遺伝子配列内の新しい調節領域はまた,リンパ球特異の遺伝子転写を保証します.
科学分野:
- 免疫学 免疫学とは
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- 免疫グロブリン (Ig) 重量 (H) 遺伝子発現は,B細胞の機能に極めて重要です.
- Ig遺伝子調節の細胞型特異性を理解することは,免疫システム研究にとって不可欠です.
研究 の 目的:
- 免疫グロブリンム重鎖 (IgH) 遺伝子発現の細胞型特異性を制御する規制要素を調査する.
- 組織特異のIg遺伝子転写に関与するIgH増強剤を超えた新しい調節領域を特定する.
主な方法:
- 組織非特異の転写単位とIg遺伝子配列を組み合わせた合成ハイブリッド遺伝子.
- これらのハイブリッド遺伝子をリンパ性および非リンパ性細胞に導入し,発現分析を行った.
- 組織特異性への影響を評価するために,IgH増強剤をウイルス増強剤に置き換えました.
主要な成果:
- リンパ球特異のIgH増強剤をウイルス増強剤に置き換えると,mu Ig遺伝子発現の組織特異性は変化しませんでした.
- ウイルス増強剤でもリンパ球特異の転写を指示するVHプロモーター領域 (-154〜+57) を特定しました.
- IgH増強剤なしのmu内遺伝子配列が,組織特異的な方法でトランスクリプトレベルを調節することを発見しました.
結論:
- Ig遺伝子発現の組織特異性は,増強剤だけでなく,複数の要素によって調節されます.
- VHプロモーターと内遺伝子配列は,リンパ球特異的な重要な規制情報を含んでいます.
- これらの発見は,Bリンパ球におけるIg遺伝子調節を制御する複雑なメカニズムについての理解を広げています.
関連する概念動画
Pulmonary Embolism III: Nursing Management
320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction
464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II
852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K